Cargando…
Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer
Androgen deprivation therapy (ADT) is the standard care for prostate cancer (PCa) patients who fail surgery or radiotherapy. While initially effective, the cancer almost always recurs as a more aggressive castration resistant prostate cancer (CRPC). Previous studies have demonstrated that chromatin...
Autores principales: | Saraç, Hilal, Morova, Tunç, Pires, Elisabete, McCullagh, James, Kaplan, Anıl, Cingöz, Ahmet, Bagci-Onder, Tugba, Önder, Tamer, Kawamura, Akane, Lack, Nathan A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7056651/ https://www.ncbi.nlm.nih.gov/pubmed/31822799 http://dx.doi.org/10.1038/s41388-019-1116-8 |
Ejemplares similares
-
EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities
por: Yedier-Bayram, Ozlem, et al.
Publicado: (2022) -
KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL
por: Kurt, Ibrahim Cagri, et al.
Publicado: (2017) -
DDRE-03. IDH1-MUTANT GBM CELLS ARE HIGHLY SENSITIVE TO COMBINATION OF KDM6A/B AND HDAC INHIBITORS
por: Kayabölen, Alişan, et al.
Publicado: (2021) -
Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival
por: Ozyerli-Goknar, Ezgi, et al.
Publicado: (2023) -
Drug Repositioning Screen on a New Primary Cell Line Identifies Potent Therapeutics for Glioblastoma
por: Senbabaoglu, Filiz, et al.
Publicado: (2020)